{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:47:41Z","timestamp":1761518861718},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2000,6]]},"DOI":"10.1007\/s11864-000-0034-9","type":"journal-article","created":{"date-parts":[[2007,7,26]],"date-time":"2007-07-26T09:14:38Z","timestamp":1185441278000},"page":"228-238","source":"Crossref","is-referenced-by-count":7,"title":["Locally advanced breast cancer"],"prefix":"10.1007","volume":"1","author":[{"given":"William M.","family":"Sikov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"34_CR1","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2366::AID-CNCR10>3.0.CO;2-N","volume":"82","author":"S Chang","year":"1998","unstructured":"Chang S, Parker SL, Pham T, et al.: Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, 1975-1992. Cancer 1998, 82:2366\u20132372.","journal-title":"Cancer"},{"key":"34_CR2","first-page":"645","volume-title":"Diseases of the Breast","author":"GN Hortobagyi","year":"2000","unstructured":"Hortobagyi GN, Singletary SE, Strom EA: Treatment of locally advanced and inflammatory breast cancer. In Diseases of the Breast, edn 2. Edited by Harris JR, Lippman ME, Morrow M, Osborne CK. Philadelphia: Lippincott Williams & Wilkins; 2000:645\u2013660. An excellent discussion of the development of current treatment approaches.","edition":"edn 2"},{"key":"34_CR3","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672\u20132685. A pivotal study of neoadjuvant versus adjuvant chemotherapy.","journal-title":"J Clin Oncol"},{"key":"34_CR4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Newman LA, Smith TL, et al.: Clinical course of breast cancer patients with complete pathologic response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460\u2013469. Analysis of long-term outcome for patients who achieve a pCR.","journal-title":"J Clin Oncol"},{"key":"34_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00000658-199907000-00011","volume":"230","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Sahin AA, Hunt KK, et al.: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999, 230:72\u201378.","journal-title":"Ann Surg"},{"key":"34_CR6","first-page":"125","volume":"4","author":"MR Machiavelli","year":"1998","unstructured":"Machiavelli MR, Romero AO, Perez JE, et al.: Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998, 4:125\u2013131.","journal-title":"Cancer J Sci Am"},{"key":"34_CR7","first-page":"75a","volume":"18","author":"E Thomas","year":"1999","unstructured":"Thomas E, Buzdar A, Hortobagyi G, et al.: Long-term follow-up of stage III breast cancer-combined modality treatment with anthracycline containing chemotherapy: the MD Anderson experience [abstract]. Proc Am Soc Clin Oncol 1999, 18:75a. Three analyses confirming the prognostic value of response to neoadjuvant treatment.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"34_CR8","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1138::AID-CNCR12>3.0.CO;2-0","volume":"79","author":"JE Olson","year":"1997","unstructured":"Olson JE, Neuberg D, Pandya K, et al.: The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 1997, 79:1138\u20131149.","journal-title":"Cancer"},{"key":"34_CR9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0360-3016(97)00897-3","volume":"40","author":"M Abdel-Wahab","year":"1998","unstructured":"Abdel-Wahab M, Wolfson A, Raub W, et al.: The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation. Int J Radiat Oncol Biol Phys 1998, 40:875\u2013880.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"34_CR10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.1997.15.1.207","volume":"15","author":"H Bortelink","year":"1997","unstructured":"Bortelink H, Rubens RD, van der Schueren E, Sylvester R: Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 1997, 15:207\u2013215.","journal-title":"J Clin Oncol"},{"key":"34_CR11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0039-6109(05)70447-3","volume":"76","author":"MJ Lopez","year":"1996","unstructured":"Lopez MJ, Porter KA: Inflammatory breast cancer. Surg Clin North Am 1996, 76:411\u2013429.","journal-title":"Surg Clin North Am"},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"466s","DOI":"10.1002\/cncr.2820741336","volume":"74","author":"CA Perez","year":"1994","unstructured":"Perez CA, Fields JN, Fracasso PM, et al.: Management of locally advanced carcinoma of the breast: II. Inflammatory carcinoma. Cancer 1994, 74:466s-476s.","journal-title":"Cancer"},{"key":"34_CR13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/BF02303668","volume":"4","author":"RY Fleming","year":"1997","unstructured":"Fleming RY, Asmar L, Buzdar AU, et al.: Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 1997, 4:452\u2013461.","journal-title":"Ann Surg Oncol"},{"key":"34_CR14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002800050664","volume":"40","author":"NT Ueno","year":"1997","unstructured":"Ueno NT, Buzdar AU, Singletary SE, et al.: Combinedmodality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson Cancer Center. Cancer Chemother Pharmacol 1997, 40:321\u2013329.","journal-title":"Cancer Chemother Pharmacol"},{"key":"34_CR15","first-page":"74a","volume":"18","author":"K Dhingra","year":"1999","unstructured":"Dhingra K, Esparza-Guerra L, Valero V, et al.: A phase III randomized trial of dose-intensive, neoadjuvant 5FU, doxorubicin, cyclophosphamide with G-CSF in locally advanced breast cancer: efficacy and safety data [abstract]. Proc Am Soc Clin Oncol 1999, 18:74a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"34_CR16","first-page":"101a","volume":"17","author":"IC Henderson","year":"1998","unstructured":"Henderson IC, Berry D, Demetri G, et al.: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17:101a. A pivotal study regarding the benefits of sequential, non-cross-resistant chemotherapy versus dose intensification.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"34_CR17","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1999.17.11.3412","volume":"17","author":"AU Buzdar","year":"1999","unstructured":"Buzdar AU, Singletary SE, Theriault RL, et al.: Prospective randomized trial of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999, 17:3412\u20133417.","journal-title":"J Clin Oncol"},{"key":"34_CR18","first-page":"68","volume":"57","author":"WM Sikov","year":"1999","unstructured":"Sikov WM, Akerley WA, Legare RD, Strenger S: Neoadjuvant high-dose weekly paclitaxel in stage IIB-IIIB breast cancer: a BrUOG study [abstract]. Breast Cancer Res Treat 1999, 57:68.","journal-title":"Breast Cancer Res Treat"},{"key":"34_CR19","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","volume":"17","author":"KD Miller","year":"1999","unstructured":"Miller KD, McCaskill-Stevens W, Sisk J, et al.: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999, 17:3033\u20133037.","journal-title":"J Clin Oncol"},{"key":"34_CR20","first-page":"72a","volume":"18","author":"O Eremin","year":"1999","unstructured":"Eremin O, Walker LG, Smith IC, et al.: Chemotherapy in breast cancer: enhanced response with docetaxel [abstract]. Proc Am Soc Clin Oncol 1999, 18:72a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"34_CR21","first-page":"73a","volume":"18","author":"P Pouillart","year":"1999","unstructured":"Pouillart P, Fumoleau P, Romieu G, et al.: Final results of a phase II randomized, parallel study of doxorubicin\/ cyclophosphamide and doxorubicin\/Taxol as neoadjuvant treatment of local-regional breast cancer [abstract]. Proc Am Soc Clin Oncol 1999, 18:73a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"34_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ajcp\/107.2.211","volume":"107","author":"AH Honkoop","year":"1997","unstructured":"Honkoop AH, Pinedo HM, De Jong JS, et al.: Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997, 107:211\u2013218.","journal-title":"Am J Clin Pathol"},{"key":"34_CR23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1200\/JCO.1993.11.4.771","volume":"11","author":"TJ Smith","year":"1993","unstructured":"Smith TJ, Hillner BE: The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993, 11:771\u2013776.","journal-title":"J Clin Oncol"},{"key":"34_CR24","first-page":"67","volume":"57","author":"G Minckwitz Von","year":"1999","unstructured":"Von Minckwitz G, Costa SD, Raab G, et al.: Randomized trial on preoperative dose-intensified adriamycindocetaxel (ADOC) vs. ADOC + tamoxifen in primary operable breast cancer [abstract]. Breast Cancer Res Treat 1999, 57:67.","journal-title":"Breast Cancer Res Treat"},{"key":"34_CR25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bjc.6690714","volume":"81","author":"P Viens","year":"1999","unstructured":"Viens P, Palangie T, Janvier M, et al.: First-line highdose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 1999, 81:449\u2013456.","journal-title":"Br J Cancer"},{"key":"34_CR26","first-page":"105a","volume":"17","author":"V Valero","year":"1998","unstructured":"Valero V, Hoff PM, Singletary SE, et al.: Combined modality treatment of locally advanced breast cancer in elderly patients using tamoxifen as primary therapy [abstract]. Proc Am Soc Clin Oncol 1998, 17:105a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"34_CR27","first-page":"104a","volume":"17","author":"JM Dixon","year":"1998","unstructured":"Dixon JM, Love CDB, Tucker S, et al.: Letrozole as primary medical therapy for locally advanced and large operable breast cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17:104a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"34_CR28","first-page":"75a","volume":"18","author":"SC Formenti","year":"1999","unstructured":"Formenti SC, Spicer D, Skinner K, et al.: Pre-operative twice weekly paclitaxel and radiation therapy in locally advanced breast cancer: molecular determinants of pathological response [abstract]. Proc Am Soc Clin Oncol 1999, 18:75a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"34_CR29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0360-3016(95)02207-4","volume":"34","author":"E Touboul","year":"1996","unstructured":"Touboul E, Buffat L, Lefranc JP, et al.: Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys 1996, 34:1019\u20131028.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"34_CR30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1999.17.3.1080","volume":"17","author":"TJ Smith","year":"1999","unstructured":"Smith TJ, Davidson NE, Schapira DV, et al.: American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999, 17:1080\u20131082.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0034-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-000-0034-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0034-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:24:20Z","timestamp":1559431460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-000-0034-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s11864-000-0034-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]}}}